We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.
- Authors
Ceresoli, G L; Cappuzzo, F; Gregorc, V; Bartolini, S; Crinò, L; Villa, E
- Abstract
Brain metastases are a common occurrence in patients with non-small-cell lung cancer (NSCLC). Whole-brain radiotherapy (WBRT) is the standard therapy; more aggressive approaches such as surgery or radiosurgery are indicated in a subset of patients only. The role of systemic treatments remains controversial. Gefitinib is an oral, highly tolerable, specific inhibitor of epidermal growth factor receptor-associated tyrosine kinase, which has shown activity in chemotherapy pre-treated NSCLC. The aim of this study was to evaluate the activity and safety of gefitinib in NSCLC patients with brain metastases.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Vol 15, Issue 7, p1042
- ISSN
0923-7534
- Publication type
Journal Article
- DOI
10.1093/annonc/mdh276